For the quarter ending 2025-09-30, AUTL made $21,194K in revenue. -$84,900K in net income. Net profit margin of -400.59%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 21,194 | 20,923 | 8,982 | - |
| Cost of sales | 28,643 | 24,445 | 17,951 | - |
| Research and development expenses, net | 27,892 | 27,430 | 26,734 | 40,323 |
| General and administrative | - | - | - | 27,330 |
| Selling, general and administrative expenses | 36,280 | 30,265 | 29,534 | - |
| Loss on disposal of property and equipment | 0 | 0 | -3 | -223 |
| Impairment of operating lease right-of-use assets and related property and equipment | 0 | 0 | - | - |
| Loss from operations | -71,621 | -61,217 | -65,240 | -67,876 |
| Other income, net | 84 | 135 | 129 | 54 |
| Foreign exchange (losses) gains, net | -911 | 1,499 | 1,181 | -11,884 |
| Interest income | 4,382 | 5,234 | 6,137 | 8,320 |
| Interest expense, net | 10,520 | -6,829 | 10,143 | 10,686 |
| Total other (expenses) income, net | -6,965 | 13,697 | -2,696 | -14,196 |
| Net loss before income tax | -78,586 | -47,520 | -67,936 | -82,072 |
| Income tax expenses | 532 | 397 | 2,225 | 22 |
| Net loss | -79,118 | -47,917 | -70,161 | -82,094 |
| Foreign currency exchange translation adjustment | -5,868 | 18,990 | 10,668 | 27,010 |
| Unrealized holding gains on available-for-sale debt securities, net of tax of 0, 0, 0 and 0, respectively | 86 | -22 | 400 | - |
| Total other comprehensive (loss) income, net of tax | -5,782 | 18,968 | 11,068 | - |
| Total comprehensive loss | -84,900 | -28,949 | -59,093 | -55,084 |
| Basic net loss per ordinary share (in usd per share) | -0.3 | -0.18 | -0.26 | -0.31 |
| Diluted net loss per ordinary share (in usd per share) | -0.3 | -0.18 | -0.26 | -0.31 |
| Weighted-average basic ordinary shares (in shares) | 266,141,431 | 266,141,411 | 266,126,548 | 266,084,589 |
| Weighted-average diluted ordinary shares (in shares) | 266,141,431 | 266,141,411 | 266,126,548 | 266,084,589 |
Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc (AUTL)